Myeloma MRD Test

Myeloma MRD Flow Cytometry Bone Marrow measures the minimal residual disease level by detecting and quantifying very small numbers of cancerous plasma cells in bone marrow samples. The technique utilizes flow cytometry to analyze the specific markers expressed on these cells.

• Assessing Treatment Response: After initial therapy, the test is used to evaluate the effectiveness of treatment by detecting any remaining cancer cells. • Disease Monitoring: Regular monitoring helps oncologists track disease progression and make informed decisions about treatment modifications. • Tailoring Treatment: MRD status influences treatment decisions, such as continuing with maintenance therapy or considering more intensive approaches. • Prognostic Value: MRD assessment provides important prognostic information and aids in predicting long-term outcomes.

Myeloma MRD Flow Cytometry Bone Marrow is recommended for: • Patients with multiple myeloma undergoing treatment. • Individuals who have completed initial therapy and are being evaluated for response. • Patients with suspected disease relapse to assess disease status. • Those undergoing stem cell transplantation to gauge the depth of response.

Abnormal results indicate the presence of minimal residual disease, suggesting that even though the disease might not be clinically evident, some cancer cells remain in the bone marrow. This information guides treatment decisions and determines the need for further therapy.

During the test, a bone marrow sample is collected and processed. Flow cytometry is then employed to analyze the sample, identifying and quantifying cancerous plasma cells based on their surface markers.

Patients might be advised to follow specific instructions provided by their healthcare provider, which could include fasting before the procedure or making adjustments to medication intake.

• Complete Blood Count (CBC): A CBC measures the levels of different blood cells, including red blood cells, white blood cells, and platelets. Abnormalities in these cell types can provide insights into the effects of multiple myeloma on the bone marrow's normal functioning. • Serum Protein Electrophoresis: These tests analyze the levels of different proteins in the blood, specifically those produced by myeloma cells. They help diagnose and monitor the disease and assess the response to treatment. • Beta-2 Microglobulin: This blood test measures the levels of a protein produced by myeloma cells and can be used as a marker of disease activity and prognosis. • Light Chain Assays (Free Light Chains): Light chains are components of immunoglobulins (antibodies) produced by myeloma cells. Elevated levels of free light chains in the blood or urine can indicate disease activity and help in monitoring. • Bone Marrow Biopsy and Aspiration: These procedures provide a more detailed examination of the bone marrow, including its cellular composition and the presence of cancerous plasma cells. They offer additional information about disease involvement and response to treatment.

• Minimal Residual Disease Assessment by Flow Cytometry in Bone Marrow • Flow Cytometric Evaluation of Residual Cancer Cells in Bone Marrow for Myeloma • Bone Marrow Minimal Residual Disease Detection using Flow Cytometry in Myeloma